Zacks: Analysts Expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Will Post Quarterly Sales of $4.38 Billion

Wall Street analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report $4.38 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $4.29 billion to $4.42 billion. Teva Pharmaceutical Industries reported sales of $4.56 billion during the same quarter last year, which indicates a negative year over year growth rate of 3.9%. The company is scheduled to report its next earnings results on Wednesday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $17.28 billion for the current year, with estimates ranging from $17.19 billion to $17.32 billion. For the next financial year, analysts expect that the business will report sales of $17.08 billion, with estimates ranging from $16.59 billion to $17.75 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The company had revenue of $4.26 billion for the quarter, compared to analysts’ expectations of $4.25 billion.

Several brokerages have weighed in on TEVA. Cowen set a $9.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Wednesday, August 7th. SunTrust Banks cut their price target on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research note on Thursday, August 8th. Guggenheim began coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a “neutral” rating for the company. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a report on Tuesday, November 12th. Finally, Raymond James lowered their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have issued a buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus target price of $10.64.

In related news, VP Hafrun Fridriksdottir sold 4,310 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total value of $45,211.90. Following the sale, the vice president now owns 24,883 shares in the company, valued at approximately $261,022.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 18,033 shares of company stock valued at $102,261. 0.49% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Point View Wealth Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 1.7% in the second quarter. Point View Wealth Management Inc. now owns 74,798 shares of the company’s stock valued at $690,000 after acquiring an additional 1,273 shares in the last quarter. CAPROCK Group Inc. lifted its holdings in Teva Pharmaceutical Industries by 6.2% in the 3rd quarter. CAPROCK Group Inc. now owns 23,730 shares of the company’s stock valued at $163,000 after purchasing an additional 1,378 shares in the last quarter. AdvisorNet Financial Inc lifted its holdings in Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after purchasing an additional 1,525 shares in the last quarter. AGF Investments America Inc. lifted its holdings in Teva Pharmaceutical Industries by 1.9% in the 2nd quarter. AGF Investments America Inc. now owns 91,897 shares of the company’s stock valued at $848,000 after purchasing an additional 1,672 shares in the last quarter. Finally, WealthTrust Axiom LLC boosted its stake in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 13,049 shares of the company’s stock worth $120,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 54.10% of the company’s stock.

TEVA traded down $0.52 on Friday, hitting $9.82. 20,033,906 shares of the company traded hands, compared to its average volume of 17,221,416. The company has a 50 day moving average of $9.16 and a 200-day moving average of $8.35. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. The stock has a market capitalization of $11.38 billion, a PE ratio of 3.51, a PEG ratio of 1.12 and a beta of 1.82. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $20.34.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: How to trade on quiet period expirations

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit